Jeremiah J Morrissey1, Evan D Kharasch. 1. Division of Clinical and Translational Research, Department of Anesthesiology, Siteman Cancer Center, Washington University in St. Louis (EDK), St. Louis, Missouri 63110-1093, USA. morrisse@wustl.edu
Abstract
PURPOSE: Renal cancer is frequently asymptomatic until late stages of the disease and it has a poor prognosis when not discovered early. AQP1 and PLIN2 are recently discovered, sensitive urine biomarkers of clear cell and papillary kidney cancer. We validated these biomarkers in a second cohort of patients and determined the effect of common kidney diseases on specificity. MATERIALS AND METHODS: Urine samples were obtained from 36 patients with clear cell or papillary kidney cancer, 43 controls, 44 patients with documented urinary tract infection, 24 diagnosed with diabetic nephropathy and 18 diagnosed with glomerulonephritis. Urine levels of AQP1 and PLIN2 normalized to urine creatinine were determined by a sensitive, specific Western blot procedure. RESULTS: Compared with controls, urine AQP1 and PLIN2 levels in patients with kidney cancer were 23-fold and fourfold greater, respectively, and they decreased 83% to 84% after tumor excision. There was a linear correlation between urine AQP1 and PLIN2 levels, and tumor size (each p <0.001). Urine AQP1 and PLIN2 levels in patients with kidney cancer were 11 to 23-fold and 17 to 25-fold greater, respectively, than in patients with the common kidney diseases. CONCLUSIONS: The ability of urine AQP1 and PLIN2 to identify patients with kidney cancer compared to controls was validated in a second cohort of patients. Common kidney diseases do not adversely increase urine AQP1 and PLIN2 levels or decrease their specificity to screen for renal cancer.
PURPOSE:Renal cancer is frequently asymptomatic until late stages of the disease and it has a poor prognosis when not discovered early. AQP1 and PLIN2 are recently discovered, sensitive urine biomarkers of clear cell and papillary kidney cancer. We validated these biomarkers in a second cohort of patients and determined the effect of common kidney diseases on specificity. MATERIALS AND METHODS: Urine samples were obtained from 36 patients with clear cell or papillary kidney cancer, 43 controls, 44 patients with documented urinary tract infection, 24 diagnosed with diabetic nephropathy and 18 diagnosed with glomerulonephritis. Urine levels of AQP1 and PLIN2 normalized to urine creatinine were determined by a sensitive, specific Western blot procedure. RESULTS: Compared with controls, urine AQP1 and PLIN2 levels in patients with kidney cancer were 23-fold and fourfold greater, respectively, and they decreased 83% to 84% after tumor excision. There was a linear correlation between urine AQP1 and PLIN2 levels, and tumor size (each p <0.001). Urine AQP1 and PLIN2 levels in patients with kidney cancer were 11 to 23-fold and 17 to 25-fold greater, respectively, than in patients with the common kidney diseases. CONCLUSIONS: The ability of urine AQP1 and PLIN2 to identify patients with kidney cancer compared to controls was validated in a second cohort of patients. Common kidney diseases do not adversely increase urine AQP1 and PLIN2 levels or decrease their specificity to screen for renal cancer.
Authors: Sinead M Kinsella; Joe P Coyle; Eva B Long; Sebastian R McWilliams; Michael M Maher; Michael R Clarkson; Joseph A Eustace Journal: Kidney Int Date: 2010-06-30 Impact factor: 10.612
Authors: Samih H Nasr; Mary E Fidler; Anthony M Valeri; Lynn D Cornell; Sanjeev Sethi; Amy Zoller; Michael B Stokes; Glen S Markowitz; Vivette D D'Agati Journal: J Am Soc Nephrol Date: 2010-11-04 Impact factor: 10.121
Authors: Andreana De Mauri; Marco Brambilla; Doriana Chiarinotti; Roberta Matheoud; Alessandro Carriero; Martino De Leo Journal: J Am Soc Nephrol Date: 2011-02-25 Impact factor: 10.121
Authors: Won K Han; Anwar Alinani; Chin-Lee Wu; Dror Michaelson; Massimo Loda; Francis J McGovern; Ravi Thadhani; Joseph V Bonventre Journal: J Am Soc Nephrol Date: 2005-03-02 Impact factor: 10.121
Authors: Jeremiah J Morrissey; Vincent M Mellnick; Jingqin Luo; Marilyn J Siegel; R Sherburne Figenshau; Sam Bhayani; Evan D Kharasch Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Xiang Shu; Mark P Purdue; Yuanqing Ye; Huakang Tu; Christopher G Wood; Nizar M Tannir; Zhaoming Wang; Demetrius Albanes; Susan M Gapstur; Victoria L Stevens; Nathaniel Rothman; Stephen J Chanock; Xifeng Wu Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-16 Impact factor: 4.254
Authors: Joseph B Song; Jeremiah J Morrissey; Jonathan M Mobley; Karen G Figenshau; Joel M Vetter; Sam B Bhayani; Evan D Kharasch; Robert Sherburne Figenshau Journal: Int J Urol Date: 2018-11-22 Impact factor: 3.369
Authors: Jeremiah J Morrissey; Jonathan Mobley; R Sherburne Figenshau; Joel Vetter; Sam Bhayani; Evan D Kharasch Journal: Mayo Clin Proc Date: 2015-01 Impact factor: 7.616
Authors: Darue A Prieto; Donald J Johann; Bih-Rong Wei; Xiaoying Ye; King C Chan; Dwight V Nissley; R Mark Simpson; Deborah E Citrin; Crystal L Mackall; W Marston Linehan; Josip Blonder Journal: Biomark Med Date: 2014 Impact factor: 2.851
Authors: Jeremiah J Morrissey; Jonathan Mobley; Joseph Song; Joel Vetter; Jingqin Luo; Sam Bhayani; R Sherburne Figenshau; Evan D Kharasch Journal: Urology Date: 2013-11-13 Impact factor: 2.649